Richard Markus

Company: Dantari, Inc.

Job title: Chief Executive Officer

Seminars:

Workshop C: From Pre-IND to IND – Overcoming Important Regulatory Hurdles to Get into the Clinic 9:00 am - 12:00 pm

Although traditional ADCs now have a developed regulatory framework, the regulatory pathway for next-generation conjugates is still developing. As more next-generation conjugates are being developed this will begin to become clearer, however, there still remains questions around the pre-IND and IND path, as well as core clinical and manufacturing regulatory challenges. This workshop will offer…Read more

day: Pre-Conference Day Track B

Beyond ADCs – Next Generation Targeted Therapeutics 11:15 am

High-capacity conjugates have advanced in parallel with that of ADCs, and now the two can be put together as next generation targeted high-capacity drug conjugates Advantages of Targeted High-capacity Drug Conjugates (T-HDCs) include: T-HDC has ~10x DAR for both targeted and bystander-mediated cell-killing High DAR allows use of moderate potent payloads and can avoid highly…Read more

day: Scientific Program Day Two